Maria Angélica Rios
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria Angélica Rios has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Luiz Alexandre Viana Magno
Medical School, Faculty of Medical Sciences of Minas Gerais, Belo Horizonte, Brazil
3 shared publications Adauto Versiani Ramos
Hospital Felício Rocho, Belo Horizonte, Brazil
1 shared publication- Camila Emanuele Moreira Fernandes
Universidade Professor Edson Antônio Velano (UNIFENAS), Belo Horizonte, Brazil
1 shared publication - Carolina Luisa Silva Nascimento
Programa de Pós-Graduação em Ciências da Saúde (PPGCS) Faculdade de Ciências Médicas de Minas Gerais (FCMMG) Belo Horizonte Brazil
1 shared publication - Cinthia Vila Nova Santana
Program for Asthma Control in Bahia (ProAR), Universidade Federal da Bahia Salvador Brazil
1 shared publication - Débora Marques de Miranda
Department of Pediatrics, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Mental Illness
- Vol. 2026 (1) , 4792471
Sleep Disturbance Scale for Children Subdomains and Depressive Severity in Youth With Major Depressive Disorder
Background: Most studies linking sleep disturbances to depressive symptoms in youth have relied on aggregate sleep scores rather than subdomain‐specific measures, leaving the role of specific sleep disturbance subdomains in clinical populations poorly understood. Objective: To examine whether specific subdomains of the Sleep Disturbance Scale for Children (SDSC) are differentially associated with depressive symptom severity in a clinical sample. Methods: Cross‐sectional study of 52 children and adolescents (mean [SD] age, 15.05 [1.27] years; 86.5% female) diagnosed with major depressive disorder (MDD) at a public, referral‐based outpatient mental health clinic in Brazil. Associations between SDSC subdomains and CDI scores were examined using age‐ and sex‐adjusted logistic (CDI ≥ 17) and continuous CDI regression. Discrimination was explored using ROC analysis. Results: Disorders of initiating and maintaining sleep (DIMS) showed the largest standardized difference between participants above and below the CDI threshold (Cohen ′ s d = 1.09, 95% CI 0.45–1.72). In a multivariable model including DIMS and sleep hyperhidrosis, only DIMS remained associated with CDI ≥ 17 (OR = 1.21, 95% CI 1.05–1.40). This pattern was consistent with CDI as a continuous outcome and after excluding the CDI sleep item. DIMS had the highest apparent AUC among individual sleep measures (0.828). Conclusions: In this predominantly female sample of children and adolescents with MDD treated in a tertiary service, DIMS was the SDSC subdomain most consistently associated with depressive symptom severity.
- 1 January 2026
- Published by Wiley in Mental Illness
- Vol. 2026 (1) , 4792471
Open AccessSleep Disturbance Scale for Children Subdomains and Depressive Severity in Youth With Major Depressive Disorder
Background: Most studies linking sleep disturbances to depressive symptoms in youth have relied on aggregate sleep scores rather than subdomain‐specific measures, leaving the role of specific sleep disturbance subdomains in clinical populations poorly understood. Objective: To examine whether specific subdomains of the Sleep Disturbance Scale for Children (SDSC) are differentially associated with depressive symptom severity in a clinical sample. Methods: Cross‐sectional study of 52 children and adolescents (mean [SD] age, 15.05 [1.27] years; 86.5% female) diagnosed with major depressive disorder (MDD) at a public, referral‐based outpatient mental health clinic in Brazil. Associations between SDSC subdomains and CDI scores were examined using age‐ and sex‐adjusted logistic (CDI ≥ 17) and continuous CDI regression. Discrimination was explored using ROC analysis. Results: Disorders of initiating and maintaining sleep (DIMS) showed the largest standardized difference between participants above and below the CDI threshold (Cohen ′ s d = 1.09, 95% CI 0.45–1.72). In a multivariable model including DIMS and sleep hyperhidrosis, only DIMS remained associated with CDI ≥ 17 (OR = 1.21, 95% CI 1.05–1.40). This pattern was consistent with CDI as a continuous outcome and after excluding the CDI sleep item. DIMS had the highest apparent AUC among individual sleep measures (0.828). Conclusions: In this predominantly female sample of children and adolescents with MDD treated in a tertiary service, DIMS was the SDSC subdomain most consistently associated with depressive symptom severity.
- 7 August 2025
- Published by Springer Nature in Brain Structure and Function
- Vol. 230 (7) , 1-15
Metabolic brain changes in post-acute COVID-19: systematic review and meta-analysis of [18F]-FDG-PET findings
Individuals with long COVID exhibit neurological and psychiatric symptoms that often persist well beyond the initial SARS-CoV-2 infection. Studies using [18F]-FDG positron emission tomography (FDG-PET) have revealed diverse abnormalities in brain glucose metabolism during the post-acute phase of COVID-19. We conducted a systematic review and meta-analysis to assess the spatial distribution and heterogeneity of brain metabolic changes in patients in the post-acute phase of COVID-19 relative to controls. We searched the MEDLINE, EMBASE, and CENTRAL databases in June 2025 for studies reporting FDG-PET data in patients with post-acute COVID-19 who have persistent neurological symptoms. Of the 14 eligible studies (584 scans), 13 reported glucose hypometabolism across frontoparietal regions, with the frontal cortex being the most consistently affected. This finding was confirmed by meta-analysis, which revealed a large and significant effect in the frontal cortex (Hedges’ g = 1.34; 95% CI: 0.79–1.88; p < 0.001), despite high heterogeneity (I2 = 93.6%). The systematic review indicates that brain metabolism generally improves over time, with widely varying recovery timelines, and consistently correlates hypometabolism with neurological symptom burden. These findings underscore the clinical relevance of frontoparietal hypometabolism in post-acute COVID-19 and its association with neurocognitive deficits, highlighting the need for longitudinal, quantitative PET studies to elucidate temporal dynamics and inform therapeutic development.
- 7 August 2025
- Published by Springer Nature in Brain Structure and Function
- Vol. 230 (7) , 1-15
Metabolic brain changes in post-acute COVID-19: systematic review and meta-analysis of [18F]-FDG-PET findings
Individuals with long COVID exhibit neurological and psychiatric symptoms that often persist well beyond the initial SARS-CoV-2 infection. Studies using [18F]-FDG positron emission tomography (FDG-PET) have revealed diverse abnormalities in brain glucose metabolism during the post-acute phase of COVID-19. We conducted a systematic review and meta-analysis to assess the spatial distribution and heterogeneity of brain metabolic changes in patients in the post-acute phase of COVID-19 relative to controls. We searched the MEDLINE, EMBASE, and CENTRAL databases in June 2025 for studies reporting FDG-PET data in patients with post-acute COVID-19 who have persistent neurological symptoms. Of the 14 eligible studies (584 scans), 13 reported glucose hypometabolism across frontoparietal regions, with the frontal cortex being the most consistently affected. This finding was confirmed by meta-analysis, which revealed a large and significant effect in the frontal cortex (Hedges’ g = 1.34; 95% CI: 0.79–1.88; p < 0.001), despite high heterogeneity (I2 = 93.6%). The systematic review indicates that brain metabolism generally improves over time, with widely varying recovery timelines, and consistently correlates hypometabolism with neurological symptom burden. These findings underscore the clinical relevance of frontoparietal hypometabolism in post-acute COVID-19 and its association with neurocognitive deficits, highlighting the need for longitudinal, quantitative PET studies to elucidate temporal dynamics and inform therapeutic development.
- Open Access
- 1 January 2024
- Published by Wiley in Journal of Obesity
- Vol. 2024 (1) , 3813621
Genetic Variations in AMPK , FOXO3A , and POMC Increase the Risk of Extreme Obesity
Objective: Genetic variability significantly impacts metabolism, weight gain, and feeding behaviors, predisposing individuals to obesity. This study explored how variations in key genes related to obesity— FOXO3A (forkhead box O3), AMPK (protein kinase AMP‐activated), and POMC (proopiomelanocortin)—are associated with extreme obesity (EOB). Methods: We conducted a case–control study with 251 EOB patients and 212 healthy controls with a body mass index (BMI) of less than 25 kg/m 2 . We genotyped 10 single nucleotide variants (SNVs) using TaqMan‐based assays. Results: Four SNVs—rs1536057 in FOXO3A , rs103685 in AMPK , rs934778, and rs6545975 in POMC —were associated with an increased risk of EOB. The strongest association was observed with rs934778 ( POMC ), which had a maximum odds ratio (OR) of 5.26 (95% CI: 2.86–9.09). While these genetic variations are closely linked to EOB, they do not affect serum glucose, triglycerides, HDL, LDL, BMI, or waist circumference. Conclusions: These findings indicate that factors beyond traditional metabolic pathways, potentially related to feeding behavior or hormonal regulation, may also link these genetic variations to obesity. Further research in a larger sample is essential to validate these findings and explore their potential to guide clinical interventions and public health strategies.
- 1 January 2024
- Published by Wiley in Journal of Obesity
- Vol. 2024 (1) , 3813621
Open AccessGenetic Variations in AMPK , FOXO3A , and POMC Increase the Risk of Extreme Obesity
Objective: Genetic variability significantly impacts metabolism, weight gain, and feeding behaviors, predisposing individuals to obesity. This study explored how variations in key genes related to obesity— FOXO3A (forkhead box O3), AMPK (protein kinase AMP‐activated), and POMC (proopiomelanocortin)—are associated with extreme obesity (EOB). Methods: We conducted a case–control study with 251 EOB patients and 212 healthy controls with a body mass index (BMI) of less than 25 kg/m 2 . We genotyped 10 single nucleotide variants (SNVs) using TaqMan‐based assays. Results: Four SNVs—rs1536057 in FOXO3A , rs103685 in AMPK , rs934778, and rs6545975 in POMC —were associated with an increased risk of EOB. The strongest association was observed with rs934778 ( POMC ), which had a maximum odds ratio (OR) of 5.26 (95% CI: 2.86–9.09). While these genetic variations are closely linked to EOB, they do not affect serum glucose, triglycerides, HDL, LDL, BMI, or waist circumference. Conclusions: These findings indicate that factors beyond traditional metabolic pathways, potentially related to feeding behavior or hormonal regulation, may also link these genetic variations to obesity. Further research in a larger sample is essential to validate these findings and explore their potential to guide clinical interventions and public health strategies.